Press Releases
Latest Recommendations for Glucose Monitoring in Settings Without Laboratory Support (AST4-A2); Performance Standards for Antimicrobial Susceptibility Testing (M100-S15); Molecular Diagnostic Methods for Infectious Diseases (MM3-P2)

Latest Recommendations for Glucose Monitoring in Settings Without Laboratory Support (AST4-A2) now available from Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS)

An increasing amount of blood glucose tests are conducted outside the laboratory, in chaotic, high-pressure hospital environments, where accuracy and exigency are at constant odds.  Improper procedures for using blood glucose meters produce inaccurate results, putting the patient at risk.  AST4-A2 provides recommendations in a straightforward Q-and-A format, designed for easy use in workplaces where time and results are in high demand.  Included are administrative structure, operator authorization, test system selection, test procedure, and quality assurance, as well as samples of a written evaluation and quality control logs.

For full press release.

Molecular Diagnostic Methods for Infectious Diseases (MM3-P2) now available from Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS)

Factors as current as the heightened threat of bioterrorism, and as gradual as increased human mobility brought about by innovations in travel, have led to a rising need for rapid identification of infectious agents.  Because nucleic acid-based methods enable the quickest possible detection and identification of microorganisms, they are in high demand by clinical laboratories.  In order to both help laboratories validate and perform the growing number of commercial assays, and to develop assays for new applications, CLSI announces the availability of Molecular Diagnostic Methods for Infectious Diseases; Proposed Guideline—Second Edition (MM3-P2).

For full press release.

Current Standards for Resistance Testing (M100-S15) now available from Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS)

CLSI's well-known antimicrobial susceptibility testing standard, Performance Standards for Antimicrobial Susceptibility Testing; Fifteenth Informational Supplement (M100-S15), has been republished, with the latest specifications for detecting emerging resistance. This standard is followed by manufacturers in the development of panels and software. In addition, the document outlines valuable and timely information about testing practices and appropriate pharmaceuticals for treating seriously ill patients.

For full press release.

  [ return to top ]